ATXI Insider Trading
Insider Ownership Percentage: 1.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $136.64
Avenue Therapeutics Share Price & Price History
Current Price: $1.85
Price Change: ▲ Price Increase of +0.1 (5.71%)
As of 01/17/2025 05:00 PM ET
Avenue Therapeutics Insider Trading History
Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
---|
11/5/2024 | Jay D Kranzler | Director | Sell | 61 | $2.24 | $136.64 | 559 | |
9/8/2023 | Fortress Biotech, Inc. | Major Shareholder | Buy | 5,578 | $54.00 | $301,212.00 | 13,765 | |
9/8/2023 | Lindsay A Md Rosenwald | Director | Buy | 4,649 | $54.00 | $251,046.00 | 4,724 | |
Avenue Therapeutics Institutional Trading History
Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
---|
10/18/2024 | Moss Adams Wealth Advisors LLC | 11,000 | $27K | 0.0% | N/A | 1.169% | |
8/15/2024 | Armistice Capital LLC | 75,000 | $0.26M | 0.0% | N/A | 7.970% | |
1/28/2022 | National Asset Management Inc. | 71,338 | $65K | 0.0% | -20.1% | 0.376% | |
11/16/2021 | National Asset Management Inc. | 89,237 | $0.13M | 0.0% | -29.2% | 0.531% | |
10/19/2021 | Kestra Advisory Services LLC | 22,500 | $34K | 0.0% | N/A | 0.134% | |
9/17/2021 | Virtu Financial LLC | 26,373 | $66K | 0.0% | N/A | 0.157% | |
9/3/2021 | Parametric Portfolio Associates LLC | 10,554 | $26K | 0.0% | -59.2% | 0.063% | |
8/16/2021 | Occudo Quantitative Strategies LP | 14,398 | $36K | 0.0% | N/A | 0.086% | |
8/13/2021 | Renaissance Technologies LLC | 78,314 | $0.20M | 0.0% | N/A | 0.468% | |
8/13/2021 | Northern Trust Corp | 13,767 | $35K | 0.0% | -82.1% | 0.082% | |
8/13/2021 | Geode Capital Management LLC | 79,556 | $0.20M | 0.0% | -40.0% | 0.475% | |
8/13/2021 | Vanguard Group Inc. | 449,982 | $1.13M | 0.0% | -35.5% | 2.687% | |
8/12/2021 | XTX Topco Ltd | 10,864 | $27K | 0.0% | N/A | 0.065% | |
8/12/2021 | Advisory Services Network LLC | 35,121 | $88K | 0.0% | N/A | 0.210% | |
8/12/2021 | Ergoteles LLC | 30,400 | $76K | 0.0% | N/A | 0.182% | |
8/10/2021 | National Asset Management Inc. | 126,037 | $0.32M | 0.0% | -26.1% | 0.753% | |
5/20/2021 | Axiom Investment Management LLC | 10,000 | $60K | 0.0% | N/A | 0.060% | |
5/19/2021 | Squarepoint Ops LLC | 11,668 | $71K | 0.0% | N/A | 0.070% | |
5/17/2021 | Goldman Sachs Group Inc. | 17,319 | $0.11M | 0.0% | N/A | 0.103% | |
5/13/2021 | Trexquant Investment LP | 13,874 | $84K | 0.0% | N/A | 0.083% | |
5/13/2021 | Axiom Investment Management LLC | 10,000 | $60K | 0.0% | N/A | 0.060% | |
5/13/2021 | Barclays PLC | 5,568 | $34K | 0.0% | +159.0% | 0.033% | |
5/12/2021 | Northern Trust Corp | 77,049 | $0.47M | 0.0% | -6.8% | 0.460% | |
5/12/2021 | Geode Capital Management LLC | 132,594 | $0.80M | 0.0% | +5.9% | 0.792% | |
2/24/2021 | Virtu Financial LLC | 17,469 | $0.10M | 0.0% | N/A | 0.104% | |
2/19/2021 | JPMorgan Chase & Co. | 17,102 | $0.10M | 0.0% | +260.2% | 0.102% | |
2/17/2021 | Jane Street Group LLC | 13,288 | $79K | 0.0% | N/A | 0.079% | |
2/11/2021 | Northern Trust Corp | 82,691 | $0.49M | 0.0% | +2.1% | 0.494% | |
2/9/2021 | Wells Fargo & Company MN | 16,406 | $98K | 0.0% | -13.2% | 0.098% | |
2/5/2021 | BlackRock Inc. | 361,486 | $2.15M | 0.0% | +5.5% | 2.158% | |
2/4/2021 | National Asset Management Inc. | 167,787 | $1M | 0.1% | +15.0% | 1.002% | |
11/13/2020 | Morgan Stanley | 22,706 | $0.25M | 0.0% | +270.9% | 0.136% | |
Data available starting January 2016
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Read More on Avenue Therapeutics
Volume
43,222 shs
Average Volume
38,106 shs
Market Capitalization
$3.79 million
P/E Ratio
0.10
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Avenue Therapeutics?